Data and Safety Monitoring Board said in a statement that it was concerned that AstraZeneca may have provided an incomplete view of the efficacy data Results from a US trial of AstraZeneca’s COVID-19 vaccine may have used “outdated information,” US federal health officials said on Tuesday. The Data and Safety Monitoring Board said in a statement that it was concerned that AstraZeneca may have provided an incomplete view of the efficacy data. AstraZeneca reported Monday that its COVID-19 vaccine provided strong protection among adults of all ages in a long-anticipated…
Read MoreUS may reconsider AstraZeneca vaccine efficacy trial data
